Nicholas J. Simon became a Gladstone trustee in 2017, serving first on the Gladstone Foundation Board.
Simon was senior managing director at Blackstone LLC from 2018–2024. He joined Blackstone as part of its acquisition of Clarus, a life sciences investment firm. Prior to joining Blackstone, Simon was co-founder and managing director of Clarus since the firm’s inception in 2005.
Simon has over 40 years of operating and investment experience in the healthcare sector and has led investments in biotechnology, pharmaceutical company partnerships, and medical technology. Before Clarus, he was a general partner at MPM Capital, a healthcare venture capital firm. From 1989 to 2000, he was at Genentech, where he was Global Head of business and corporate development. Simon has served on over 30 private and public companies and is currently serving on the board of directors of Autolus Therapeutics, SFJ Pharmaceuticals and Uniquity Bio, Inc. He is also on the board of visitors of MD Anderson Cancer Center and former trustee of the California Academy of Sciences.
Simon received a BS degree in microbiology from the University of Maryland and an MBA from Loyola University.
